Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel diseaseCitation formats

  • External authors:
  • Christian P. Selinger
  • Jayne Eaden
  • D. Brian Jones
  • Peter Katelaris
  • Grace Chapman
  • Charles McDonald
  • Paul Smith
  • Simon Lal
  • Rupert W. Leong
  • John McLaughlin
  • Andrew Robinson

Standard

Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. / Mclaughlin, John; Selinger, Christian P.; Eaden, Jayne; Brian Jones, D.; Katelaris, Peter; Chapman, Grace; McDonald, Charles; Smith, Paul; Lal, Simon; Leong, Rupert W.; McLaughlin, John; Robinson, Andrew.

In: Inflammatory Bowel Diseases, Vol. 19, No. 10, 09.2013, p. 2199-2206.

Research output: Contribution to journalArticle

Harvard

Mclaughlin, J, Selinger, CP, Eaden, J, Brian Jones, D, Katelaris, P, Chapman, G, McDonald, C, Smith, P, Lal, S, Leong, RW, McLaughlin, J & Robinson, A 2013, 'Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease', Inflammatory Bowel Diseases, vol. 19, no. 10, pp. 2199-2206. https://doi.org/10.1097/MIB.0b013e31829ed8a6

APA

Mclaughlin, J., Selinger, C. P., Eaden, J., Brian Jones, D., Katelaris, P., Chapman, G., ... Robinson, A. (2013). Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. Inflammatory Bowel Diseases, 19(10), 2199-2206. https://doi.org/10.1097/MIB.0b013e31829ed8a6

Vancouver

Mclaughlin J, Selinger CP, Eaden J, Brian Jones D, Katelaris P, Chapman G et al. Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. Inflammatory Bowel Diseases. 2013 Sep;19(10):2199-2206. https://doi.org/10.1097/MIB.0b013e31829ed8a6

Author

Mclaughlin, John ; Selinger, Christian P. ; Eaden, Jayne ; Brian Jones, D. ; Katelaris, Peter ; Chapman, Grace ; McDonald, Charles ; Smith, Paul ; Lal, Simon ; Leong, Rupert W. ; McLaughlin, John ; Robinson, Andrew. / Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease. In: Inflammatory Bowel Diseases. 2013 ; Vol. 19, No. 10. pp. 2199-2206.

Bibtex

@article{d7147d9ef2de48f08929b730d06bca8f,
title = "Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease",
abstract = "Background: Poor adherence frequently impaired the efficacy of therapy to maintain remission from inflammatory bowel diseases (IBD). There is a lack of practical and effective interventions to improve adherence. This study aimed to identify modifiable risk factors, which may yield targets for new interventions. Methods: Participants with IBD were recruited from hospital outpatient clinics and office-based gastroenterologists. Demographic and disease-related data were recorded by means of self-administered questionnaires. Modifiable risk factors were assessed with the validated Belief about Medicine Questionnaire, Hospital Anxiety and Depression Score, and short inflammatory bowel disease questionnaire. Adherence was assessed separately for 5-aminosalicylates, thiopurines, and biological agents using the validated Medicine Adherence Report Scale (good adherence defined as >16). Results: Nonadherence occurred in 102 of 356 participants (28.7{\%}). Adherence increased significantly with more aggressive therapies (median Medicine Adherence Report Scale: 5-aminosalicylates 18, thiopurines 19, biological 20; P <0.0001). Nonadherence was not associated with anxiety and depression or disease-related patient knowledge. Adherent patients had significantly higher belief of necessity for medication (P <0.0001) and a trend toward lower concerns about medication (P = 0.08). Membership of an IBD patient organization was associated with better adherence (P <0.0001). Concerns about medication rose significantly with more aggressive therapies (P = 0.009), but belief of necessity was similar for all medications. Conclusions: Nonadherence occurs most frequently with 5-aminosalicylates. Belief of necessity may prove the key target for future interventions, although general IBD education is unlikely to yield an adherence benefit. Patient organization membership should be encouraged. Copyright {\circledC} 2013 Crohn's & Colitis Foundation of America, Inc.",
keywords = "Adherence, Aminosalycilates in IBD, Biologic therapies, Compliance issues in IBD, Immunomodulators, Psychosocial aspects of IBD",
author = "John Mclaughlin and Selinger, {Christian P.} and Jayne Eaden and {Brian Jones}, D. and Peter Katelaris and Grace Chapman and Charles McDonald and Paul Smith and Simon Lal and Leong, {Rupert W.} and John McLaughlin and Andrew Robinson",
year = "2013",
month = "9",
doi = "10.1097/MIB.0b013e31829ed8a6",
language = "English",
volume = "19",
pages = "2199--2206",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley & Sons Ltd",
number = "10",

}

RIS

TY - JOUR

T1 - Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease

AU - Mclaughlin, John

AU - Selinger, Christian P.

AU - Eaden, Jayne

AU - Brian Jones, D.

AU - Katelaris, Peter

AU - Chapman, Grace

AU - McDonald, Charles

AU - Smith, Paul

AU - Lal, Simon

AU - Leong, Rupert W.

AU - McLaughlin, John

AU - Robinson, Andrew

PY - 2013/9

Y1 - 2013/9

N2 - Background: Poor adherence frequently impaired the efficacy of therapy to maintain remission from inflammatory bowel diseases (IBD). There is a lack of practical and effective interventions to improve adherence. This study aimed to identify modifiable risk factors, which may yield targets for new interventions. Methods: Participants with IBD were recruited from hospital outpatient clinics and office-based gastroenterologists. Demographic and disease-related data were recorded by means of self-administered questionnaires. Modifiable risk factors were assessed with the validated Belief about Medicine Questionnaire, Hospital Anxiety and Depression Score, and short inflammatory bowel disease questionnaire. Adherence was assessed separately for 5-aminosalicylates, thiopurines, and biological agents using the validated Medicine Adherence Report Scale (good adherence defined as >16). Results: Nonadherence occurred in 102 of 356 participants (28.7%). Adherence increased significantly with more aggressive therapies (median Medicine Adherence Report Scale: 5-aminosalicylates 18, thiopurines 19, biological 20; P <0.0001). Nonadherence was not associated with anxiety and depression or disease-related patient knowledge. Adherent patients had significantly higher belief of necessity for medication (P <0.0001) and a trend toward lower concerns about medication (P = 0.08). Membership of an IBD patient organization was associated with better adherence (P <0.0001). Concerns about medication rose significantly with more aggressive therapies (P = 0.009), but belief of necessity was similar for all medications. Conclusions: Nonadherence occurs most frequently with 5-aminosalicylates. Belief of necessity may prove the key target for future interventions, although general IBD education is unlikely to yield an adherence benefit. Patient organization membership should be encouraged. Copyright © 2013 Crohn's & Colitis Foundation of America, Inc.

AB - Background: Poor adherence frequently impaired the efficacy of therapy to maintain remission from inflammatory bowel diseases (IBD). There is a lack of practical and effective interventions to improve adherence. This study aimed to identify modifiable risk factors, which may yield targets for new interventions. Methods: Participants with IBD were recruited from hospital outpatient clinics and office-based gastroenterologists. Demographic and disease-related data were recorded by means of self-administered questionnaires. Modifiable risk factors were assessed with the validated Belief about Medicine Questionnaire, Hospital Anxiety and Depression Score, and short inflammatory bowel disease questionnaire. Adherence was assessed separately for 5-aminosalicylates, thiopurines, and biological agents using the validated Medicine Adherence Report Scale (good adherence defined as >16). Results: Nonadherence occurred in 102 of 356 participants (28.7%). Adherence increased significantly with more aggressive therapies (median Medicine Adherence Report Scale: 5-aminosalicylates 18, thiopurines 19, biological 20; P <0.0001). Nonadherence was not associated with anxiety and depression or disease-related patient knowledge. Adherent patients had significantly higher belief of necessity for medication (P <0.0001) and a trend toward lower concerns about medication (P = 0.08). Membership of an IBD patient organization was associated with better adherence (P <0.0001). Concerns about medication rose significantly with more aggressive therapies (P = 0.009), but belief of necessity was similar for all medications. Conclusions: Nonadherence occurs most frequently with 5-aminosalicylates. Belief of necessity may prove the key target for future interventions, although general IBD education is unlikely to yield an adherence benefit. Patient organization membership should be encouraged. Copyright © 2013 Crohn's & Colitis Foundation of America, Inc.

KW - Adherence

KW - Aminosalycilates in IBD

KW - Biologic therapies

KW - Compliance issues in IBD

KW - Immunomodulators

KW - Psychosocial aspects of IBD

U2 - 10.1097/MIB.0b013e31829ed8a6

DO - 10.1097/MIB.0b013e31829ed8a6

M3 - Article

VL - 19

SP - 2199

EP - 2206

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 10

ER -